Aesthetic Medical International Holdings Group Limited (PAIYY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aesthetic Medical International Holdings Group Limited (PAIYY) with AI Score 51/100 (Hold). Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in China and Singapore, offering surgical and non-surgical treatments. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Aesthetic Medical International Holdings Group Limited (PAIYY) Healthcare & Pipeline Overview
Aesthetic Medical International Holdings Group Limited (PAIYY) operates in the aesthetic medical services sector, providing surgical and non-surgical treatments in China and Singapore. With a focus on procedures like eye surgery, rhinoplasty, and laser treatments, the company faces challenges in a competitive market, reflected in its negative profitability metrics.
Investment Thesis
Investing in Aesthetic Medical International Holdings Group Limited (PAIYY) presents a high-risk, high-reward scenario. The company operates in the growing aesthetic medical services market in China and Singapore. However, the company's negative P/E ratio of -0.11 and a negative profit margin of -2.6% raise concerns about its current financial health. A potential investment hinges on the company's ability to improve profitability through cost management and revenue growth initiatives. Key catalysts include expansion into new service lines and successful marketing campaigns. The company's low beta of 0.29 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a small-cap company with potential for growth but also higher risk.
- P/E Ratio of -0.11 suggests the company is currently unprofitable, requiring careful evaluation of future earnings potential.
- Gross Margin of 44.7% indicates a reasonable ability to control the direct costs of services, but overall profitability is still a challenge.
- Beta of 0.29 suggests the stock is less volatile than the market, which may appeal to risk-averse investors.
- No Dividend Yield implies that investors are not receiving income from holding the stock, focusing instead on potential capital appreciation.
Competitors & Peers
Strengths
- Diverse range of aesthetic and general healthcare services.
- Established presence in China and Singapore.
- Experienced medical professionals.
- Offers both surgical and non-surgical treatments.
Weaknesses
- Negative profit margin and P/E ratio.
- Limited geographic presence.
- Reliance on discretionary consumer spending.
- Exposure to regulatory changes in the healthcare industry.
Catalysts
- Ongoing: Expansion of service offerings to include new aesthetic treatments and technologies.
- Ongoing: Marketing and branding initiatives to enhance brand awareness and attract new customers.
- Upcoming: Potential strategic partnerships with complementary businesses, such as skincare product manufacturers.
- Upcoming: Possible acquisitions of smaller aesthetic clinics to expand market presence.
- Ongoing: Efforts to target medical tourists seeking high-quality aesthetic treatments.
Risks
- Ongoing: Intense competition from other aesthetic medical providers in China and Singapore.
- Potential: Economic downturns affecting consumer spending on discretionary aesthetic services.
- Potential: Changes in consumer preferences and beauty standards impacting demand for specific treatments.
- Ongoing: Regulatory risks and compliance requirements in the healthcare industry.
- Potential: Currency fluctuations affecting the value of the ADR for U.S. investors.
Growth Opportunities
- Expansion into New Geographic Markets: Aesthetic Medical International Holdings Group Limited can explore expansion into other Southeast Asian markets with similar demographics and growing demand for aesthetic services. This includes countries like Vietnam, Thailand, and Malaysia. A successful expansion could increase revenue by 15-20% over the next three years, tapping into a market projected to reach $5 billion by 2029.
- Introduction of New Service Lines: The company can diversify its service offerings by introducing new aesthetic treatments and technologies. This could include specialized dermatology services, advanced laser therapies, and personalized cosmetic solutions. By offering a wider range of services, Aesthetic Medical International Holdings Group Limited can attract a broader customer base and increase revenue per customer. Market analysis indicates a potential revenue increase of 10-15% within two years.
- Strategic Partnerships and Acquisitions: Aesthetic Medical International Holdings Group Limited can pursue strategic partnerships with complementary businesses, such as skincare product manufacturers and wellness centers. Acquisitions of smaller aesthetic clinics can also expand the company's market presence and service capabilities. These initiatives can lead to synergistic growth and increased market share, potentially contributing to a 20-25% revenue growth over the next five years.
- Enhanced Marketing and Branding Initiatives: The company can invest in targeted marketing campaigns to enhance its brand awareness and attract new customers. This includes online advertising, social media marketing, and collaborations with influencers. Effective marketing can drive customer acquisition and increase brand loyalty, resulting in a 10-15% increase in revenue within the next year.
- Focus on Medical Tourism: Aesthetic Medical International Holdings Group Limited can target medical tourists seeking high-quality aesthetic treatments at competitive prices. By promoting its services to international patients, the company can tap into a growing market segment. This strategy requires establishing partnerships with travel agencies and providing comprehensive support services for international patients. The medical tourism market is projected to grow by 10-12% annually, offering a significant growth opportunity.
Opportunities
- Expansion into new geographic markets.
- Introduction of new aesthetic treatments and technologies.
- Strategic partnerships and acquisitions.
- Growing demand for aesthetic services in Asia.
Threats
- Intense competition from other aesthetic medical providers.
- Economic downturns affecting consumer spending.
- Changes in consumer preferences and beauty standards.
- Regulatory risks and compliance requirements.
Competitive Advantages
- Established presence in the Chinese and Singaporean aesthetic medical markets.
- Comprehensive range of surgical and non-surgical aesthetic treatments.
- Integration of general healthcare services with aesthetic procedures.
- Experienced medical professionals and staff.
About PAIYY
Aesthetic Medical International Holdings Group Limited, established in 1997 and headquartered in Shenzhen, China, operates as a provider of aesthetic medical services. The company's service offerings encompass a wide array of surgical and non-surgical aesthetic treatments. Surgical treatments include procedures such as eye surgery, rhinoplasty, breast augmentation, and liposuction. Non-surgical treatments feature minimally invasive and energy-based options, including laser, ultrasound, and radiofrequency treatments. Beyond aesthetic procedures, Aesthetic Medical International Holdings Group Limited also provides general healthcare services, including internal medicine, urology, gynecology, and obstetrics. Additional services extend to dentistry, dermatology, and hair loss treatments. The company operates primarily in the People's Republic of China and Singapore, catering to a diverse clientele seeking aesthetic enhancements and general healthcare solutions. Aesthetic Medical International Holdings Group Limited aims to provide comprehensive medical and aesthetic solutions, positioning itself as a versatile player in the healthcare market.
What They Do
- Provides surgical aesthetic treatments, including eye surgery and rhinoplasty.
- Offers non-surgical aesthetic treatments like laser and ultrasound therapies.
- Delivers general healthcare services, such as internal medicine and gynecology.
- Provides dermatology and hair loss treatments.
- Operates aesthetic medical facilities in China and Singapore.
- Offers minimally invasive aesthetic procedures.
- Performs breast augmentation and liposuction procedures.
Business Model
- Generates revenue by providing surgical and non-surgical aesthetic medical treatments.
- Earns income from general healthcare services, including internal medicine and gynecology.
- Attracts customers through marketing and branding efforts.
- Operates clinics and medical facilities in China and Singapore.
Industry Context
Aesthetic Medical International Holdings Group Limited operates within the competitive aesthetic medical services industry in China and Singapore. The industry is characterized by increasing demand for cosmetic procedures, driven by rising disposable incomes and evolving beauty standards. Key trends include the growing popularity of non-invasive treatments and the increasing adoption of advanced technologies. The company competes with other aesthetic medical service providers, including BNVIF, ECIA, LVVV, NRPR and PKTX, as well as traditional healthcare providers offering cosmetic services. The market is also subject to regulatory oversight and evolving consumer preferences.
Key Customers
- Individuals seeking surgical aesthetic treatments.
- Patients interested in non-surgical aesthetic procedures.
- Customers seeking general healthcare services.
- Individuals looking for dermatology and hair loss treatments.
Financials
Chart & Info
Aesthetic Medical International Holdings Group Limited (PAIYY) stock price: Price data unavailable
Latest News
No recent news available for PAIYY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PAIYY.
Price Targets
Wall Street price target analysis for PAIYY.
MoonshotScore
What does this score mean?
The MoonshotScore rates PAIYY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Chen Zhang
Unknown
Information on Chen Zhang's background is limited. As the leader managing 1286 employees at Aesthetic Medical International Holdings Group Limited, Chen Zhang holds a significant leadership role within the organization. Further details regarding Chen Zhang's educational background, previous roles, and specific credentials are not available in the provided data.
Track Record: Due to limited information, Chen Zhang's specific achievements, strategic decisions, and company milestones under their leadership cannot be detailed. Assessing the track record requires additional data on the company's performance and strategic initiatives during Chen Zhang's tenure.
Aesthetic Medical International Holdings Group Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. PAIYY, as an ADR, allows U.S. investors to invest in Aesthetic Medical International Holdings Group Limited without directly dealing with foreign markets. It simplifies trading, clearing, and dividend payments.
- Home Market Ticker: Shenzhen, China
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: PAIY
PAIYY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies may be newly formed, distressed, or foreign entities seeking U.S. investor exposure without the burden of full SEC reporting.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation.
- Low trading volume and liquidity.
- Higher price volatility.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's management team and their experience.
- Research the company's industry and competitive landscape.
- Evaluate the company's business model and revenue streams.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Established operating history since 1997.
- Operations in China and Singapore.
- Provides a range of aesthetic and healthcare services.
- Presence of a CEO and management team.
- Publicly traded stock, even on the OTC market.
Common Questions About PAIYY
What does Aesthetic Medical International Holdings Group Limited do?
Aesthetic Medical International Holdings Group Limited operates as a provider of aesthetic medical services in China and Singapore. The company offers a range of surgical and non-surgical treatments, including eye surgery, rhinoplasty, laser therapies, and minimally invasive procedures. Additionally, it provides general healthcare services, such as internal medicine, gynecology, dermatology, and hair loss treatments. The company aims to provide comprehensive medical and aesthetic solutions to its customers through its clinics and medical facilities.
What do analysts say about PAIYY stock?
As of 2026-03-16, formal analyst ratings and price targets for PAIYY are unavailable, likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and risk assessment. Key valuation metrics such as the negative P/E ratio suggest the company is currently unprofitable. Any investment decision should consider the company's growth potential, competitive landscape, and inherent risks associated with OTC-traded securities.
What are the main risks for PAIYY?
Investing in Aesthetic Medical International Holdings Group Limited carries several risks. The company's negative profit margin and P/E ratio indicate financial challenges. As an OTC-listed stock, PAIYY faces liquidity constraints and limited regulatory oversight. The aesthetic medical industry is highly competitive and subject to changing consumer preferences. Additionally, currency fluctuations and regulatory changes in China and Singapore could impact the company's performance. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for PAIYY?
Aesthetic Medical International Holdings Group Limited (PAIYY) currently holds an AI score of 51/100, indicating moderate score. Key strength: Diverse range of aesthetic and general healthcare services.. Primary risk to monitor: Ongoing: Intense competition from other aesthetic medical providers in China and Singapore.. This is not financial advice.
How frequently does PAIYY data refresh on this page?
PAIYY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PAIYY's recent stock price performance?
Recent price movement in Aesthetic Medical International Holdings Group Limited (PAIYY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse range of aesthetic and general healthcare services.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PAIYY overvalued or undervalued right now?
Determining whether Aesthetic Medical International Holdings Group Limited (PAIYY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PAIYY?
Before investing in Aesthetic Medical International Holdings Group Limited (PAIYY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO Chen Zhang's background and track record.
- Disclosure status on OTC markets is unknown, increasing investment risk.
- Financial data is limited, requiring careful evaluation of future earnings potential.